Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Trial

NCT07465263 is registered in ClinicalTrials.gov with CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. as lead sponsor.

NCT NCT07465263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07465263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Trial
Lead sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
March 31, 2026
Completion date
May 31, 2028
Enrollment
135 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia (hefh)